Depression
Conditions
Interventions
treatment group:oral drug administration
Sponsors
Peking University Sixth Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18 ~ 65 years (including borderline values), regardless of gender. 2. Meeting DSM-5 diagnostic criteria for depression and current depressive episode in accordance with the Mini-International Neuropsychiatric Interview 7.0 (MINI 7.0). 3. A total score of MADRS =26. 4. A total score of DARS (Chinese version) =28.5 5. No antidepressants or mood stabilizers in the last 2 weeks, no benzodiazepines or other sleep aids in the last 3 days, and no fluoxetine or vortioxetine in the last 1 month. 6. Subjects voluntarily participated in this trial and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergy or known allergy to venlafaxine or desvenlafaxine. 2. Those whose previous treatment with venlafaxine have failed , or whose treatment with at least 2 different types of antidepressants are ineffective. 3. Persons with severe self-injury, significant suicidal attempts or behaviors, with a MADRS entry 10 (suicidal ideation) score = 4 4. Pregnant or lactating women, recent planned pregnancy and use of contraceptives 5. Consistent with a DSM-5 diagnosis of any disorder other than depression 6. Substance related or alcohol use disorders (excluding nicotine or caffeine) meeting DSM-5 diagnostic criteria within 6 months before screening 7. Persons with depressive episodes secondary to other psychiatric or somatic disorders 8. Persons with a history of seizures (except convulsions caused by pediatric febrile convulsions) 9. Total bilirubin (TBIL) values 1.5 times higher than the upper limit of normal, alanine aminotransferase (ALT) or glutamic oxalacetic aminotransferase (AST) 2 times higher than the upper limit of normal, creatinine (Cr) 1.2 times higher than the upper limit of normal, and thyroid stimulating hormone (TSH) outside the normal range at screening. 10. Electrocardiogram (ECG) abnormalities that are clinically significant at the time of screening and that the investigator considers inappropriate for inclusion, such as QTc interval > 470 ms in men and QTc interval > 480 ms in women. 11. Those who have participated in other clinical trials within 3 months prior to screening. 12. Other serious acute or chronic diseases, psychiatric disorders, or abnormal laboratory examination have clinical significance , and the investigator has judged that the subject is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DARS;SHAPS; | — |
Secondary
| Measure | Time frame |
|---|---|
| SDS;Q-LES-Q-SF;MADRS; | — |
Countries
China
Contacts
Public ContactLu Lin
Peking University Sixth Hospital
Outcome results
None listed